In a small cell therapy trial, 10 out of 12 people with type 1 diabetes no longer needed supplemental insulin, even a year after treatment.

IcoSema, a combination therapy of basal insulin icodec and semaglutide, achieves a noninferior reduction in A1c levels compared with basal-bolus therapy in adults with T2D.

Pregnant women with type 1 diabetes who used hybrid closed-loop insulin delivery with Control-IQ technology spent more time ...

After a one-year follow-up, 10 of 12 patients given the islet cell therapy zimislecel no longer required insulin. Vertex ...

The addition of anagliptin to insulin and metformin therapy may improve glycemic control in patients with type 2 diabetes while maintaining an acceptable safety profile.

In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to ...

Children with diabetes who inhaled their mealtime doses of insulin did just as well as those who injected insulin under the ...

In a clinical trial led by University of Toronto researchers, an allogeneic stem cell–derived islet therapy (zimislecel) ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Insulin-producing human pancreas cells can be manufactured with 3D printers, researchers reported at the International Transplant Congress underway in London.

CHICAGO -- An investigational allogeneic stem cell-derived islet-cell therapy helped almost all patients with type 1 diabetes ...